
Tissue Regenix appoints Sanofi VP
pharmafile | July 18, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | couldwell, tissue regenix
Medical devices firm Tissue Regenix has appointed Steven Couldwell as a non-executive director.
With over 14 years of senior management experience, Couldwell is currently vice president and head of Global Biosurgery at Sanofi, and has a proven international track record driving revenues and profit growth in both the medical device and CRO industries.
His appointment follows that of Randeep Singh Grewal to non-executive director announced last week. Couldwell will provide support to the firm’s management team with his experience of building successful international businesses based on pioneering technology.
Couldwell was also formerly VP and general manager of Covance Laboratories Europe, and worked for Smith & Nephew for almost 20 years in a number of roles including President Orthopaedics (Europe) and senior VP Sales and Marketing for Smith & Nephew’s Advanced Wound Management business.
John Samuel, executive chairman of Tissue Regenix, said: “We are confident that Steven’s proven international experience in the medical device sector will make a major contribution to the future of the Group.
“His particular expertise in the orthopaedic and wound care sectors will prove extremely beneficial and complements Randeep Singh Grewal’s investment expertise. Steven and Randeep’s appointments will be invaluable as the Group progresses towards full commercialisation of our product range over the coming months and years.”






